com case kickoff_novo
TRANSCRIPT
PARVANEH SADEGHI Parvaneh is a laboratory technician in Research & Development in Novo NordiskDenmark
ComCase ‘15 Kickoff event
CBS, 27 November 2014
Mike Rulis & Charlotte Ersbøll
Novo TerapeutiskLaboratorium 1925
Merger of Novo Industriand Nordisk Gentofte 1989
Novo Nordisk 2000Nordisk Insulinlaboratorium1923
Novozymes 2000
The short version of our history
2Novo Nordisk - Corporate Presentation
14th largest pharmaceutical company in terms of sales (2013)
3
-
10,000
20,000
30,000
40,000
50,000
60,000
70,000
80,000
Billio
n U
S d
ollar
Sales
4
Our global presence
5Novo Nordisk - Corporate presentation
3 strategic R&D centresChina, Denmark, US
5 Strategic production sitesBrazil, China, Denmark, France, US
5 Regional headquartersChina, Japan, Europe, IO, North America
Global headquartersDenmark
75 affiliates
Novo Nordisk markets its products in 180 countries worldwide
Employees by region in 75 countries
We are more than 40,000 employees
6Novo Nordisk - Corporate presentation
1. Includes headquarter functions, R&D, production sites and sales office.
The objective of the Novo Nordisk Foundation is twofold:
• to provide a stable basis for the commercial and research activities conducted by the companies within the Novo Group
• to award significant amounts for scientific and humanitarian purposes
The Novo Nordisk Foundation approves the allocation of profits within Novo A/S.
Novo A/S is a holding company wholly-owned by the Novo Nordisk Foundation. Novo A/S manages the Foundation’s broad portfolio of financial assets through investments in the life science area.
Novo A/S is the majority shareholder in the listed companies Novo Nordisk A/S and Novozymes A/S.
Novo A/S holds 25.5% of the total share capital and 73% of the total number of votes. Other shareholders hold 74.5% of the total share capital and 27% of the total number of votes.
Novo Nordisk A/S is listed on NASDAQ OMX Copenhagen and New York Stock Exchange.
Ownership structure
7Novo Nordisk - Corporate Presentation
Novo Nordisk’s corporate strategy
8
Core capabilities
Expand leadership in
DIABETES
Pursue leadership in
HAEMOPHILIA
Establish presence in
OBESITY
Expand leadership in
GROWTH DISORDERS
Strategic priorities
Novo Nordisk Way
Engineering, formulating, developing and delivering protein-based treatments
Building and maintaining a leading position inemerging markets
Deep disease understanding
Efficient large-scale production of proteins
Planning and executing global launches of new products
The Novo Nordisk WayHow we want to achieve success
Our ambition is to strengthen our leadership in diabetes.
We aspire to change possibilities in haemophilia and other serious chronic conditions.
Our key contribution is to discover and develop innovative biological medicines and make them accessible to patients throughout the world.
9
The Triple Bottom Line
Introduction course 10
Patients
The diabetes pandemic
11
People waiting at a diabetes clinic in Tanzania
VL45 presentation
The global diabetes challenge
12
• Risk factors include:
• Urbanisation and rapid socio-economic transition – the ‘mismatch theory’
• Obesity
• Poor diet
• Physical inactivity
• Advancing age
• Family history in diabetes
• Ethnicity
• Gestational diabetes – risk for both mother and child
Why the explosive growth in type 2 diabetes?
13
14
The ‘Rule of Halves’ a story of missed opportunities
Actual rates of diagnosis, treatment, targets and outcomes vary in different countries
Diabetes – a European snapshot
15
1 in 3 people with diabetes do not know they have it
1 in 12 adults have diabetes
Diabetes costs 116 billion euros in direct health expenditures in Europe in 2014
Use Novo Nordisk’s diabetes products every day
16
24.3
Novo Nordisk Changing Diabetes
KOFI ANNAN and LISE KINGOSetting the agenda for change2013 IDLF, Turkey
17
18
Changing Diabetes®
Start with “why”
• “People don't buy what you do; they buy why you do it. And what you do simply proves what you believe.”
• “If you hire people just because they can do a job, they’ll work for your money. But if you hire people who believe what you believe, they’ll work for you with blood and sweat and tears.”
Simon Sinek, Author of “Start with why”
18
Changing Diabetes® is our promise to improve health and quality of life
Expand access to affordable care worldwide
Improve health outcomes for people with diabetes
• DAWN2
• Changing Diabetes®
barometer
• Healthcare professionals and patient training
• Action on Diabetes
• Changing Diabetes® 40by20 Patient Ambition
• LDC pricing policy
• Changing Diabetes® at the Base of the Pyramid
• Changing Diabetes® in Children
Prevent diabetes in future generations
• Changing Diabetes® in Pregnancy
• Changing Future Health
Drive awareness and public policy
• World Diabetes Day
• Changing Diabetes® Leadership Forums
• Changing Diabetes® Village
• Team Novo Nordisk
19
Changing Diabetes®
goes hand-in-hand with our business
Changing Diabetes® plans take their starting point in diabetes rule of halves with prioritised Changing Diabetes® actions where societal needs intersect with business opportunity
20
Presentation title Date 21
Novo NordiskAccess to Health
Strategy
Differential Pricing for LDCs
2011
World Partner Project
Oxford Health Alliance
Denmark and Russia
Support to UN Resolution
on Diabetes
20142001
Building on 10 years of Changing Diabetes®
New York
China
23
Changing Diabetes®
A Platform for strengthening stakeholder relations
UN adoption of Resolution on
diabetes
UN High-Level meeting on NCDs
2006 2007 2008 2009 2010 2011 2012 2013 2014
NCDs recognised in Rio+20 outcome
document
Novo Nordisk
World events
Europe Turkey Europe, Latin America & Pakistan
MENA & Africa ChinaRussiaUSA
First UN observed World Diabetes Day
WHO target on NCDs
2015
Changing Diabetes® Leadership ForumsThe journey
Post 2015: NCDs in UN Sustainable Development Goals
24
Leadership Forums put change on the agenda
Since 2007, we have convened 9 international and 52 national diabetes leadership forums.
13,000 high-level policy stakeholders and decision makers have engaged in the question of changing diabetes in 40 countries
Pursuing our goal to push diabetes to the top of the political and healthcare agenda around the world
25
Source: Novo Nordisk internal documents.
LARS REBIEN SØRENSEN, HRH CROWN PRINCE FREDERIK OF DENMARK, PRESIDENT BILL CLINTON, HH SHEIKH RASHID BIN HAMDAN AL MAKTOUM and MAKTOUM HASSAN ALI AL QASSAM. MENA Forum 2010 in Dubai, United Arab Emirates
17 countries
International Diabetes
Federation (IDF)
Steno Diabetes Center
International Alliance of Patient
Organizations (IAPO)
15,438 respondents
8,596 people with diabetes
2,057 family members
4,785 diabetes care professionals
Patient organisations and policy makers
1. Nicolucci A, et al. Diabet Med 2013;30:767–77; 2. Kovacs Burns K, et al. Diabet Med 2013;30:778–883. Holt RIG, et al. Diabet Med 2013;30:789–98
DAWN2™ - the world’s largest psychosocial studyWe start with the patient
26
The DAWN2™ study revealed that
• 19% of people with diabetes feel discriminated against because of their condition
• 37% of family members feel frustrated because they do not know how best to help their relative with diabetes
• 45% of people with diabetes experience diabetes-related distress
VERÓNICA RUBIO FRANCO WITH HER CHILDRENMexico
Verónica had gestational diabetesand now has type 2 diabetes
27
Team Novo Nordisk: racing to change diabetes
Team Novo Nordisk is a world-class sports programme for athletes with diabetes.
Their mission is to educate, empower and inspire people affected by diabetes. Team Novo Nordisk shows that it is possible for people with diabetes to live full lives and achieve ambitious personal goals.
Team Novo NordiskProfessional cycling team
28
The Fight against Urban Diabetes
29
Urban health: Emerging & untapped opportunity
Many cities face a triple threat:• Infectious diseases• Chronic, non-communicable diseases• Accidents, injuries, road accidents,
violence, and crime
Dr Margaret Chan, Director-General, WHO
One of my pet peeves is that obesity and diabetes – and their connection to community design – are virtually ignored by health scientists in the world of environmental advocacy, who remain almost exclusively focused on pollution
Dr Richard Jackson, MD, MPHDesigning Healthy Communities, Atlantic Cities
The rise of city mayors
“City leaders also govern the places where this century's most intractable problems play out – and where solutions are most likely to be found.”
“The White House Would Be a Step Down.No elective office can match the New York City mayoralty as a source of direct action to improve everyday life.”
“New York's next mayor needs to be ready to go global. “
Launched in Mexico City 25 March
32
In Mexico City we have the building blocks to tackle urban diabetes.”
The new frontline
• My argument today is that these two trends are related: global cities and global diabetes
• We believe that focusing on cities is the new frontline of the fight against diabetes
• What we need now is a wake-up call
• We need to make sure that urban diabetes is always on the agenda when people take decisions about managing cities
• We want to put this issue right to the top of the agenda of the global healthcare community
• We need a global fight against urban diabetes
- Lars Rebien Sørensen, Mexico City
34
Public-private partnerships
Global fight against urban diabetes
Urban diabetes is on the rise
Cities Changing Diabetes is our response
Activities
• Map the diabetes challenge in selected big cities across the world
• Share learning and best practices on how to break the Rule of Halves
• Implement action plans with local partners
México City28 March 2014
Copenhagen 22 August 2014
City partners
Houston3 November 2014
Tianjin13 November 2014
Shanghai14 November 2014
Cities Changing Diabetes aims to break the Rule of Halves and stop urban diabetes from ruining millions of lives
First-wave citiesNeed, business, opportunity, global spread
35
By 2025, 136 new cities are expected to enter the top 600, all of them from the developing world and overwhelmingly—100 new cities—from China.
McKinsey Global Institute
Mexico City
Houston
Copenhagen
Tianjin
36
The A
pis
bull lo
go is
a re
gis
tere
d tra
dem
ark
of N
ovo N
ord
isk A
/S38